- Company
- AI-based liquid biopsy companies deliver tangible results
- by Son, Hyung-Min Mar 28, 2024 05:52am
- Domestic companies have started to deliver tangible results with their liquid biopsy technology. The early cancer diagnosis accuracy of GC Genome’s ai-CANCERCH and IMBdx’s CancerFind were found to be over 80%. EDGC's (Eone-Diagnomics Genome Center) test showed an 80% sensitivity in diagnosing colorectal cancer. Liquid biopsy detects disease
- Policy
- LG Chem expands its Zemimet SR Tab lineup
- by Lee, Tak-Sun Mar 28, 2024 05:52am
- A new dosage form of LG Chem's diabetes combination drug ‘Zemimet SR Tab (gemigliptin /metformin) will be added to the reimbursement list next month. This is expected to increase prescription options in the field and allow fully personalized prescriptions for the patients. According to industry sources on the 27th, Zemimet SR Tab 2
- Company
- Dt&CRO signs MOU with U.S. company Radyus Research
- by Nho, Byung Chul Mar 27, 2024 06:04am
- On the 25th, Dt&CRO announced that it had signed a memorandum of understanding (MOU) with Radyus Research, a U.S. clinical consulting organization. The MOU is expected to add momentum to the company’s full-cycle consulting service that is provided to domestic pharma and biotech companies that apply for Investigational New Drug (IND) or
- Policy
- Ruling party will focus on fostering Korea's pharma industry
- by Lee, Jeong-Hwan Mar 27, 2024 06:04am
- The ruling party has adopted a number of policies proposed by domestic pharmaceutical companies and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association as pledges for the 22nd general election, foretelling its plan to concentrate on fostering the domestic pharmaceutical industry. The ruling party's main pledge, which is to c
- Policy
- 'Trajenta-duo' generics as SR tablets…55 approved items
- by Lee, Hye-Kyung Mar 27, 2024 06:04am
- As the patent expiration of 'Trajenta-duo (linagliptin and metformin),' a DPP-4 inhibitor combination therapy for the treatment of diabetes, approaches, approvals of sustained-release formulations are increasing. According to the Ministry of Food and Drug Safety (MFDS), as of March 26th, 55 tablets containing the active ingredients linaglipt
- Company
- No news on Phesgo's reimb progress for 7 months
- by Eo, Yun-Ho Mar 27, 2024 06:04am
- The insurance reimbursement process for Phesgo, a drug that was expected to benefit from the preferential drug pricing system, is making little progress. No news has been heard on its progress for 7 months. Roche Korea’s Perjeta (pertuzumab+ trastuzumab), a subcutaneous injectable combination of the company’s Perjeta and Herceptin, pass
- Company
- Adtralza reimb drives biologics competition in atopy market
- by Eo, Yun-Ho Mar 26, 2024 06:30am
- Biopharmaceuticals face competition in the atopic dermatitis sector. According to industry sources, LEO Pharma’s Adtralza (tralokinumab), a treatment for atopic dermatitis with an underlying mechanism of neutralizing interleukin-13 (IL-13), is anticipated to launch with reimbursement starting in May. Adtralza is the second biologic
- Company
- Sam Chun Dang Pharm introduces Eylea biosimilar to Europe
- by Nho, Byung Chul Mar 26, 2024 06:30am
- Sam Chun Dang Pharm announced on the 25th an exclusive distribution agreement for the Eylea biosimilar with nine Western European countries (UK, Belgium, Netherlands, Norway, Portugal, Sweden, Greece, Ireland, and Finland). Under the agreement, Sam Chun Dang Pharm will receive 55% of the partnering company’s net sales, further strength
- Policy
- MFDS reviews enacting a separate and special law for drugs
- by Lee, Hye-Kyung Mar 26, 2024 06:30am
- The Ministry of Food and Drug Safety (MFDS) is considering enacting a 'special law' to separately manage drug safety management. For this, the MFDS recently launched a call for researchers for the ‘Study for the Analysis of the Legal System of the Pharmaceutical Affairs Act and Review of the Special Act on Drug Safety Management'. The
- Company
- Takeda’s colorectal cancer drug 'Fruzaqla' nears KOR entry
- by Eo, Yun-Ho Mar 26, 2024 06:30am
- New colorectal cancer drug 'Fruzaqla' is likely to receive approval for commercialization in South Korea. According to industry sources on the 11th, Takeda Pharmaceuticals Korea’s Fruzaqla (fruquintinib), designated as Global Innovative products on Fast Track (GIFT) by the Ministry of Food and Drug Safety (MFDS), is under review for app
